Extract from M&A Insights

M&A Insights is our fully-fledged M&A platform for teams operating in the Nordics and DACH countries, enabling clients to identify and qualify opportunities well in advance of any structured process.
Lundbeck makes an offer to buy Prexton Therapeutics
March 19, 2018

Lundbeck makes an offer to buy Prexton Therapeutics for 100M EUR now and will pay up to 805M EUR down the line in case the drug Foliglurax reaches a set of milestones. One of the big winners is the Danish venture capital fund Sunstone Capital who owns approximately one-fifth of Prexton Therapeutics and bought their shares in 2015.

ⓘ This story was originally featured in our daily M&A Newsletter - a part of M&A Insights.
Our insights have been covered by: